Apis Mellifera Arctostaphylos Uva-Ursi Leaf Arseni

證據等級: L5

預測適應症: 0 個

Multi-Component Herbal/Homeopathic Complex: Insufficient Data for Repurposing Assessment

One-Sentence Summary

This candidate is a seven-ingredient complex containing APIS MELLIFERA, ARCTOSTAPHYLOS UVA-URSI LEAF, ARSENIC TRIOXIDE, CALCIUM SULFIDE, LYTTA VESICATORIA, SMILAX ORNATA ROOT, and SOLIDAGO VIRGAUREA FLOWERING TOP — a profile consistent with a homeopathic or naturopathic combination product. The TxGNN model returned no predicted new indications for this multi-ingredient entry, which most likely occurs because the pipeline could not resolve the composite INN to a single DrugBank node. Without a prediction target, a standard repurposing evaluation cannot be completed at this time.

Quick Overview

Item	Content
Original Indication	None on record (not registered in the US)
Predicted New Indication	No TxGNN prediction available
TxGNN Prediction Score	N/A
Evidence Level	L5 — model prediction only (currently no prediction generated)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why Is No Prediction Available?

The TxGNN knowledge graph operates on individual DrugBank-mapped entities. This submission lists seven distinct botanical, mineral, and zoological ingredients as a single INN string, separated by semicolons. Because the pipeline could not resolve the composite string to a single DrugBank ID (drugbank_id: null), the graph traversal had no valid starting node and returned an empty prediction set.

Each component, taken individually, carries its own pharmacological profile:

Arsenic Trioxide — a well-characterised antineoplastic agent approved for acute promyelocytic leukaemia (APL); its mechanism involves degradation of the PML-RARα fusion protein and induction of apoptosis in leukaemic cells.
Arctostaphylos Uva-Ursi Leaf — contains arbutin, a urinary antiseptic with documented use in lower urinary tract infections.
Solidago Virgaurea — traditionally used as a diuretic and for urinary tract inflammation; supported by European monographs (EMA/HMPC).
Lytta Vesicatoria — source of cantharidin; historically applied in homeopathy for genitourinary complaints.
Apis Mellifera, Calcium Sulfide, Smilax Ornata Root — used in homeopathic preparations; limited evidence base in conventional pharmacology.

The combination profile (heavy urinary-tract ingredients + one potent cytotoxic component) does not map cleanly to a single disease target, which further explains the absent prediction.

Cytotoxicity Note

Note: Arsenic trioxide is one of the seven listed components. Because it is a recognised antineoplastic agent, the following cytotoxicity considerations apply if arsenic trioxide constitutes a therapeutically active portion of this formulation.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — heavy metal / pro-apoptotic agent (arsenic trioxide component)
Myelosuppression Risk	Please refer to arsenic trioxide package insert; leucocytosis and differentiation syndrome are known risks in APL treatment
Emetogenicity Classification	Low to moderate (arsenic trioxide monotherapy class)
Monitoring Items	ECG (QTc prolongation), CBC with differential, liver and renal function, serum electrolytes (K⁺, Mg²⁺)
Handling Protection	If arsenic trioxide is a quantifiable active ingredient, cytotoxic drug handling regulations apply

Safety Considerations

Please refer to the individual component package inserts and the prescribing information for arsenic trioxide for safety information. No combined-product safety data, DDI records, or registered warnings were found for this multi-ingredient entry.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline could not generate a repurposing prediction because the composite INN could not be resolved to a DrugBank node; without a prediction target, repurposing evaluation is blocked at the entry point. Additionally, the product has zero US regulatory authorisations and no safety profile on record.

To proceed, the following is needed:

Decompose the query: Submit each of the seven ingredients as separate TxGNN queries (e.g., Arsenic Trioxide → DrugBank DB01169) and aggregate individual predictions.
Identify the intended formulation: Confirm whether this is a homeopathic, naturopathic, or combination prescription product, and obtain the corresponding product monograph or package insert.
Resolve MOA data gap (DG002): Query DrugBank for each active ingredient individually to obtain mechanism-of-action data.
Obtain safety data (DG001): Retrieve package insert warnings and contraindications for arsenic trioxide specifically, as it carries a black-box warning (APL differentiation syndrome, QTc prolongation, hepatotoxicity).
Clarify regulatory status: Determine if this product is registered in any jurisdiction under a homeopathic or traditional medicine pathway, which would provide an original indication for anchoring repurposing analysis.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.